Speaking with your healthcare professional about hereditary ATTR (hATTR) amyloidosis

Learning about this condition and your family health history can help you have a conversation with your healthcare professional


The path to diagnosis

Symptoms of hATTR amyloidosis may be similar to those of other conditions.

The more educated you are about the symptoms, the better prepared you can be to speak with your healthcare professional about a possible diagnosis.

It’s important that you discuss all the symptoms you’re experiencing because your healthcare professional may choose to refer you to a specialist who could prescribe further tests to help make a diagnosis.

Conditions with symptoms that may appear to be similar to those of hATTR amyloidosis

This list may not be all-inclusive.

Conditions associated with polyneuropathy
Chronic inflammatory demyelinating polyneuropathy (CIDP)
Amyotrophic lateral sclerosis (ALS)
Motor polyradiculoneuropathy
Carpal tunnel syndrome
Idiopathic polyneuropathy
Paraneoplastic neuropathy
Motor neuron disease
Charcot-Marie-Tooth disease
Alcoholic neuropathy
Diabetic neuropathy
Amyloid light (AL) chain amyloidosis
Amyloid A (AA) amyloidosis

Conditions associated with cardiomyopathy
Hypertensive heart disease
Hypertrophic cardiomyopathy
Fabry disease
Amyloid light (AL) chain amyloidosis

If you experience symptoms and are aware of a family history, speak to your healthcare professional—he or she can conduct an evaluation and determine the right plan of action. Because the condition affects different parts of the body, it may be necessary for your healthcare professional to refer you to a specialist who is familiar with hATTR amyloidosis.



Adams D, Curr Opin Neurol. 2016;29(suppl 1):S14-S26.
Conceição I, J Peripher Nerv Syst. 2016;21(1):5-9.
Ando Y, 2013;8:31.
Ruberg DL, Circulation. 2012;126(10):1286-1300.
Adams D, Curr Neurol Neurosci Rep. 2014;14(3):435.
Adams D, Curr Opin Neurol. 2012;25(5):564-572.
Szigeti K, Eur J Hum Genet. 2009;17(6):703-710.
Zeng L, J Pain Res. 2017;10:219-228.
Shin SC, Mt Sinai J Med. 2012;79(6):733-748.
Lalande S, Drugs Today (Barc). 2008;44(7):503-513.
Rapezzi C, Amyloid. 2012;19(suppl 1):16-21.
Linart A, The heart in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (eds). Fabry Condition: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 20.